ACTRIMS 2022 | Research developments in MOGAD

Michael Levy, MD, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA, discusses the latest developments in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) treatment and management. Due to its distinct pathophysiological features, MOGAD is emerging as its own disease entity; the presence of autoantibodies against MOG distinguishes it from related neuroinflammatory and demyelinating disorders. Dr Levy comments on progress being made in our understanding of disease biology, epidemiology, and clinical presentation of MOGAD. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.